Goodwin Names 40 New Partners

 Global law firm Goodwin today announced that 40 lawyers have been elected to the firm’s partnership, effective October 1, 2023.  

“This year's new partner class is a group of exceptionally talented lawyers who exemplify the best of who we are as a firm,” said Anthony McCusker, Goodwin’s Chair. “Their leadership and commitment to the firm’s clients, culture, and core principles are the reason Goodwin continues to be a top choice for clients and talent. We are thrilled to welcome them to the partnership.”

Goodwin congratulates: 

	Reid Bagwell (Private Equity, Boston) focuses on representing a diverse range of clients, including private equity sponsors and their portfolio companies, REITs, public companies and lenders in connection with syndicated and private financing transactions.
	John Barker (Complex Litigation & Dispute Resolution – Securities Litigation, Boston) focuses on complex securities litigation and commercial disputes. He advises and defends companies, directors, and officers in a wide variety of legal disputes, including federal securities class actions, derivative and fiduciary duty litigation, corporate governance matters, arbitration, and M&A litigation.
	Matthew Baudler (Technology, San Francisco) focuses on mergers and acquisitions and has extensive transactional experience advising public and private companies, financial sponsors and investors in M&A transactions and minority investments across a number of industries, including technology, digital media, e-commerce, financial technology, cannabis, healthcare, and consumer products.
	David Brekke (Technology, San Francisco) focuses on corporate formations, venture capital financings, mergers and acquisitions, strategic transactions, and corporate governance for clients operating primarily in the climate technology and sustainability innovation spaces.
	Gerard Cedrone (Complex Litigation & Dispute Resolution – Appellate, Boston) focuses on appellate matters, complex commercial litigation, and life science disputes, with particular experience in administrative law, patent law, and constitutional law.
	Katherine Cheng (Complex Litigation & Dispute Resolution – Healthcare Litigation, Washington) focuses on antitrust, consumer protection, and other high-stakes competitive disputes touching on a wide variety of areas such as complex commercial litigation, contract issues, business torts, and unfair competition. Her practice has a special emphasis on healthcare, life sciences, technology, and other industries experiencing disruption and innovation.
	Nicole Chessari (Complex Litigation & Dispute Resolution – Securities Litigation, Silicon Valley) focuses on working with technology and life sciences companies and private investment firms in connection with complex commercial litigation, pre- and post-close M&A litigation, securities litigation, internal investigations, and government investigations.
	Stacy Dasaro (Financial Restructuring, New York) represents debtors, creditors, investors and other key stakeholders in both in-court and out-of-court restructurings across a variety of industries, including retail, pharmaceuticals, financial services, hospitality, energy, real estate, and manufacturing.
	Niall Dickson (Real Estate Industry, London) focuses on the structuring, formation, restructuring and ongoing management of private investment funds and other structured investment vehicles in the real estate, venture capital, credit, and private equity sectors.
	James Ding (Technology, New York) focuses his practice on mergers and acquisitions, corporate governance, activist defense, and general corporate matters. He has extensive experience representing public and private acquirers and target companies, in domestic and cross-border transactions, and across technology, life sciences, industrials, financial services, and additional industries.
	Lauren Falkowitz (Private Equity, Boston) focuses on all aspects of the formation, operation and ongoing maintenance of private investment funds, including private equity funds, venture capital funds, co-investments, fund-of-funds, secondaries and other investment advisory businesses in the United States and internationally.
	Matthew Feuerman (Real Estate Industry, Boston) represents clients in commercial real estate transactions involving a variety of asset classes. His experience spans the asset lifecycle, including complex joint ventures, restructurings and recapitalizations, mortgage, construction and mezzanine financings, and asset-level and entity-level acquisitions and dispositions.
	Brian Fleming (Private Equity, Boston) focuses on mergers, acquisitions, private equity investments, and other corporate matters in a wide range of industries. Specifically, he has experience representing both corporate strategic and private equity clients in structuring, negotiating, documenting and closing mergers, acquisitions and dispositions, including assisting private equity funds with the purchase, ongoing representation, and sale of portfolio companies.
	Matthew Hacker (Private Equity, Boston) specializes in advising private equity sponsors and their portfolio companies in connection with an array of investment transactions, including domestic and cross-border mergers and acquisitions, leveraged buyouts, recapitalizations, growth equity investments and divestitures, as well as general corporate matters.
	Daniel Hughes (Life Sciences, Boston) advises clients on a wide range of matters, including start-up and formation, venture capital financings, mergers and acquisitions, initial public offering, capital markets transactions, private equity investments, and general corporate and securities law. He is also a Chartered Financial Analyst.
	Michael Jones (Private Equity, Boston) focuses primarily on mergers and acquisitions, leveraged buyouts, private equity investments, strategic transactions and other general corporate matters in a broad range of industries. He has experience in representing clients in the acquisition, ongoing representation, and eventual sale of portfolio companies.
	Elizabeth Jordan (Private Equity, Boston) focuses on representing a diverse range of clients, including private equity sponsors and their portfolio companies, public companies, and lenders, in connection with syndicated and private financing transactions.
	Ananth Lakshman (Private Equity, Singapore) focuses on cross border transactions for venture capital and private equity sponsors and their respective portfolio companies, and has extensive experience in mergers and acquisitions, buyouts, joint ventures, co-investments, early and late-stage venture capital, and growth equity investments across a wide variety of sectors and industries.
	Ann Seung-Eun Lee (Real Estate Industry, San Francisco) focuses on structuring and negotiating and closing complex commercial real estate transactions, including joint ventures, acquisitions and dispositions, financings and development projects involving all asset classes, including hotels, residential properties, industrial properties, and commercial office buildings.
	Kevin Liu (Technology, San Francisco) counsels clients with respect to a broad array of licensing and intellectual property matters in connection with their day-to-day business operations, venture financings, M&A transactions, and initial public offerings.
	Cecelia Lockner (Complex Litigation & Dispute Resolution – Risk Management & Insurance, Boston) focuses on advising private equity, hedge fund and corporate clients on matters related to directors and officers (D&O) liability and insurance, professional liability insurance for financial institutions, and transactional liability insurance (including representation and warranty (R&W) insurance, tax indemnity insurance and litigation buyout policies).
	Mary FitzSimons McQuinn (Real Estate Industry, Washington) represents investors and operators in the structuring, negotiation, drafting and the closing of complex commercial real estate transactions, including joint ventures, acquisitions and dispositions, financings, management agreements and development projects involving all asset classes, including office, multifamily residential, hotels and resorts and mixed-use hospitality projects.
	Brian Mulhall (Technology, New York) focuses on the technology sector with a primary focus on mergers & acquisitions, venture financings, growth equity, joint ventures and general representation of emerging growth companies.
	C.J. Murray (Private Equity, Boston) focuses primarily on mergers and acquisitions, leveraged buyouts, private equity investments, strategic transactions, and other general corporate matters in a broad range of industries.
	Justin Pierce (Global Trade, Washington) advises on national security and international trade regulations associated with the Committee on Foreign Investment in the United States (CFIUS), economic sanctions administered by the Office of Foreign Assets Control, and export controls under the Export Administration Regulations and the International Traffic in Arms Regulations.
	Robert Powers (Private Equity, Philadelphia) focuses primarily on mergers and acquisitions, with an emphasis on representing private equity sponsors and their portfolio companies in a wide variety of transactions and industries.
	John Quinn (Private Equity, Boston) specializes in advising private equity sponsors and their portfolio companies in a wide variety of transactions, including leveraged buyouts, mergers, acquisitions, growth equity investments and other corporate matters.
	Amanda Russo (Complex Litigation & Dispute Resolution – Commercial Litigation, Food & Healthy Living, Los Angeles) focuses on both complex civil litigation and regulatory advising and counseling for corporate clients in a variety of industries, with a particular focus in the consumer products space, including companies in the food and beverage, dietary supplement and personal care/cosmetics industries, as well as in the financial and technology industries.
	Daniel Saposnik (Technology M&A, Silicon Valley) advises buyers, founders, investors and private equity sponsors on complex mergers and acquisition transactions and private equity investments.
	Simon Servan-Schreiber (Private Equity, Paris) advises on a broad range of corporate matters, with a focus on private equity transactions. He has particular experience advising private equity houses and management teams in mid-market buyouts.
	Elliot Silver (Complex Litigation & Dispute Resolution – Antitrust, Washington) concentrates his practice on antitrust transactional, litigation and advisory matters, as well as issues pertaining to all aspects of sports law.
	Tierney Smith (Complex Litigation & Dispute Resolution – CFS Litigation & Enforcement, Washington) focuses her practice on civil litigation and government enforcement matters, with particular emphasis on the banking and consumer financial services industries.
	Sarah Stoiber (Life Sciences, Boston) represents biotechnology, pharmaceutical, medical device, diagnostic and other life sciences companies in connection with their intellectual property, commercial, and M&A transactions.
	Caitlin Tompkins (Real Estate Industry, Boston) focuses on a variety of corporate and securities matters, including public and private offerings of securities, securities law compliance and corporate governance matters. She also advises public and private companies across a broad range of industries in mergers and acquisitions.
	Bastien Voisin (Tax, Luxembourg) advises asset managers, institutional investors, multinational technology and life sciences companies on all aspects of international taxation and cross-border structuring.
	Sebastian Walczak (Private Equity, Munich) focuses on national and international private equity transactions, mergers and acquisitions and joint ventures, as well as general corporate matters representing private equity funds, asset managers, strategic investors and domestic and international corporate clients with regard to leveraged buy-outs, management buy-outs, management incentive plans, and joint ventures.
	Zhenghui (Alan) Wang, Ph.D. (Life Sciences, New York) represents pharmaceutical, biotechnology, diagnostic and medical device companies in domestic and cross-border complex life sciences and technology transactions, including co-development, licensing and collaboration, manufacturing, supply and distribution, M&A, and other intellectual property transactions.